- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07938645
PARP Inhibition for Biliary Tract Cancer With Mutations in Core and Non-Core Homologous Recombination Deficiency Genes (IKF-IMMUPARP)
Phase II Study of Immunotherapy Plus PARP Inhibition Maintenance for Platinum-Sensitive Biliary Tract Cancer With Mutations in Core- and Non-Core Homologous Recombination Deficiency Genes
The IMMUPARP study is an open-label, multicenter phase II trial investigating maintenance therapy with olaparib plus durvalumab in patients with platinum-sensitive advanced biliary tract cancer harboring homologous recombination deficiency (HRD)-associated gene alterations after response or stable disease on first-line chemoimmunotherapy.
연구 개요
상세 설명
The goal of this phase II clinical trial is to evaluate the efficacy and safety of maintenance therapy with the PARP inhibitor olaparib in combination with the PD-L1 inhibitor durvalumab in adult patients with platinum-sensitive unresectable locally advanced or metastatic biliary tract cancer (BTC) harboring homologous recombination deficiency (HRD)-associated gene alterations. Eligible patients must have achieved stable disease or an objective response following first-line treatment with gemcitabine, cisplatin and immunotherapy.
The main questions it aims to answer are:
Does maintenance treatment with olaparib plus durvalumab result in a clinically meaningful progression-free survival (PFS) rate at 6 months? What are the progression-free survival, overall survival, response outcomes, and duration of disease control associated with this treatment approach? What is the safety and tolerability profile of olaparib plus durvalumab maintenance therapy? How does maintenance treatment affect patient-reported quality of life?
This is a prospective, multicenter, open-label, non-randomized phase II trial consisting of two cohorts. Cohort 1 includes patients with alterations in core HRD genes (e.g., BRCA1, BRCA2, PALB2 or RAD51C/D), while Cohort 2 includes patients with alterations in non-core HRD genes.
There is no comparison group. All participants will receive study treatment consisting of olaparib administered orally twice daily and durvalumab administered intravenously every 4 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or completion of the protocol-defined treatment period.
Participants will:
Receive olaparib and durvalumab maintenance therapy. Undergo regular tumor assessments by CT or MRI every 8 weeks. Complete quality-of-life questionnaires during the study. Undergo routine safety assessments, including physical examinations and laboratory testing.
Optionally provide blood and tumor samples for translational biomarker analyses, including evaluation of HRD status and circulating tumor DNA (ctDNA).
The study aims to generate prospective evidence on the clinical activity of combined PARP inhibition and immune checkpoint blockade as a maintenance strategy in molecularly selected patients with advanced BTC.
Up to 40 patients will be enrolled across both cohorts.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Anna Saborowski, PD Dr.
- 전화번호: 0049511 5326779
- 이메일: saborowski.anna@mh-hannover.de
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patient* has given written informed consent.
-
Patient is, in the investigator's judgement, willing and able to comply with the trial protocol.
-
Patient is ≥ 18 years of age at time of signing the written informed consent.
-
Patient has been diagnosed with histologically confirmed unresectable locally advanced or metastatic biliary tract cancer.
-
Patient has platinum-sensitive BTC, i.e., shows stable disease or partial response after at least 4 months of SOC treatment with GemCis plus durvalumab.
-
Cohort 1 only: Patient has BTC with mutations in Core HRD genes, including germline/somatic (gs) mutation of BRCA1, BRCA2, PALB2 or RAD51C/D (assessed by local testing) or Cohort 2 only: BTC with mutations in Non-Core HRD genes, including ATM, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51B, RTEL1, MUTYH (assessed by local testing) .
-
Patient has ECOG performance status ≤ 1.
-
Patient has adequate hepatic, renal and hematologic functions:
- Absolute number of neutrophils (ANC) ≥ 1.5 x 109/L
- Platelets ≥ 100x103/µL
- Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L (Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within the last 2 weeks)
- Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl; measured and calculated per institutional standard) ≥ 60 mL/min (i.e., if serum creatinine level is > 1.5 x upper limit of normal [ULN]). GFR can also be used instead of creatinine or CrCl.
- AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN (or ≤ 5.0 x ULN if liver metastases are present)
- Total Bilirubin ≤ 1.5 x ULN (or direct bilirubin ≤ ULN for patients with total bilirubin levels >1.5× ULN)
- International normalized ratio (INR) OR prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless patient is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants.
-
Male patients must agree to use a contraception as detailed in Appendix 5 of this protocol during the treatment period and for at least 3 months after the last dose of trial treatment (and refrain from donating sperm during this period.
Female patients are eligible to participate if they are not pregnant (see Appendix 5), not breastfeeding, and at least one of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) as defined in Appendix 5 OR
- A WOCBP who agrees to follow the contraceptive guidance as given in Appendix 5 during the treatment period and for at least 6 months after the last dose of trial intervention 10. Patient has measurable disease based on RECIST v1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
Exclusion Criteria:
-
Patient has any known contraindication including hypersensitivity to any component of the PARP inhibitor or durvalumabformulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein.
-
Patient has received prior treatment with PARP inhibitors.
-
Patient is currently participating in or has participated in a trial of an investigational medicinal product or has used an investigational medicinal product within 4 weeks prior to the first dose of trial intervention.
NOTE: Patients who have entered the follow-up phase of an investigational trial may participate as long as it has been 4 weeks after the last dose of the previous investigational medicinal product .
-
Patient has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial drug.
-
Patient has known additional malignancy that is progressing or has required active treatment within the past 3 years.
Note: Participants with low risk localized prostate cancer, basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded.
-
Patient has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during trial screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of trial intervention.
-
Patient has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
-
Patient has a history of pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
-
Patient has an active infection requiring systemic therapy.
-
Patient has a known history of Human Immunodeficiency Virus (HIV) infection.
-
Patients with known Hepatitis B and C infection expect the following:
-
Hepatitis B positive subjects
- Patients who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load (< 100 IU/mL) prior to enrollment
- Patients should remain on anti-viral therapy throughout trial intervention and follow local guidelines for HBV anti-viral therapy post completion of trial intervention.
-
Patients with a history of HCV infection are eligible if HCV viral load is undetectable at screening.
- Patients must have completed curative anti-viral therapy at least 4 weeks prior to enrollment.
NOTE: Hepatitis B and C screening tests are not required unless there is a known history of HBV or HCV infection and/or as mandated by local health authority
-
-
Patient has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, such that it is not in the best interest of the patient to participate, in the opinion of the treating investigator.
-
Patient has had an allogenic tissue / solid organ transplant.
-
Patients who are pregnant or breastfeeding or expect to conceive (female patients) within 6 months or father children (male patients) within the projected duration of the trial, starting with the screening visit through 3 months after the last dose of trial treatment.
-
Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan, previous allogenic bone marrow/blood transplantation or any psychiatric disorder or substance abuse that prohibits obtaining informed consent
-
Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
-
Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
-
Patients who are dependent on the sponsor, the investigator or the trial site.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Cohort 1: Core HRD
Experimental maintenance: Olaparib: orally, 2 x 300 mg daily, continuously PLUS Durvalumab: 1,500 mg, i.v., on day 1 of every 4-week cycle (Q4W) Patients will receive treatment until progression, unacceptable toxicity, withdrawal of consent, or end of protocol-defined treatment (maximum of 12 months). |
Experimental maintenance: Olaparib: orally, 2 x 300 mg daily, continuously PLUS Durvalumab: 1,500 mg, i.v., on day 1 of every 4-week cycle (Q4W) (maximum of 12 months). |
|
실험적: Cohort 2: Non-Core HRD
Experimental maintenance: Olaparib: orally, 2 x 300 mg daily, continuously PLUS Durvalumab: 1,500 mg, i.v., on day 1 of every 4-week cycle (Q4W) Patients will receive treatment until progression, unacceptable toxicity, withdrawal of consent, or end of protocol-defined treatment (maximum of 12 months). |
Experimental maintenance: Olaparib: orally, 2 x 300 mg daily, continuously PLUS Durvalumab: 1,500 mg, i.v., on day 1 of every 4-week cycle (Q4W) (maximum of 12 months). |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
PFS rate at 6 months
기간: 6 months after start of maintenance therapy
|
PFS rate at 6 months (PFS@6), defined as proportion of patients alive and progression-free at 6 months after start of maintenance therapy |
6 months after start of maintenance therapy
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall response rate
기간: up to 12 months
|
Overall response rate (ORR), defined as proportion of patients achieving complete or partial response (CR/PR) acc. to RECIST v1.1. |
up to 12 months
|
|
Overall survival
기간: up to 36 months
|
Overall survival (OS), defined as time from start of induction therapy until date of death due to any cause. |
up to 36 months
|
|
Overall survival (OSmaint)
기간: up to 36 months
|
Overall survival (OSmaint), defined as time from start of maintenance therapy until date of death due to any cause. |
up to 36 months
|
|
Progression-free survival
기간: up to 36 months
|
Progression-free survival (PFS), defined as time from start of induction therapy until date of progression acc. to RECIST v1.1 or death due to any cause. |
up to 36 months
|
|
Progression-free survival (PFSmaint)
기간: up to 36 months
|
Progression-free survival (PFSmaint), defined as time from start of maintenance therapy until date of progression acc. to RECIST v1.1 or death due to any cause. |
up to 36 months
|
|
Quality of life (QoL) data (EORTC QLQ-C30) Functional Scale Scores
기간: up to 13 months
|
Quality of life will be assessed using the EORTC QLQ-C30 questionnaire. Functional scale scores (Physical Functioning, Role Functioning, Emotional Functioning, Cognitive Functioning, and Social Functioning) are transformed to a 0-100 scale. Scores range from 0 to 100, with higher scores indicating better functioning |
up to 13 months
|
|
Safety
기간: up to 15 months (max. 12 months treatment plus 90 days for immune-mediated AEs)
|
Assessment of safety of the treatment as determined by the incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 6.0 |
up to 15 months (max. 12 months treatment plus 90 days for immune-mediated AEs)
|
|
Quality of life (QoL) data (EORTC QLQ-C30) Symptom Scale Scores
기간: up to 13 months
|
Quality of life will be assessed using the EORTC QLQ-C30 questionnaire. Symptom scale and single-item scores are transformed to a 0-100 scale. Scores range from 0 to 100, with higher scores indicating greater symptom burden and worse quality of life. |
up to 13 months
|
|
Quality of life (QoL) data (EQ-5D-5L) Health Utility Index Score
기간: up to 13 months
|
Health status will be assessed using the EQ-5D-5L descriptive system. The health utility index score is calculated from the five EQ-5D-5L dimensions using the applicable country-specific value set. The score typically ranges from values below 0 (health states worse than death) to 1.0 (full health). Higher scores indicate better health status. |
up to 13 months
|
|
Quality of life (QoL) data (EQ-5D-5L) Visual Analogue Scale (VAS) Score
기간: up to 13 months
|
Health status will be assessed using the EQ-5D-5L Visual Analogue Scale (VAS). Scores range from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. Higher scores indicate better perceived health |
up to 13 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Salah Al-Batran, Prof. Dr., Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .